TELA Bio, Inc. (TELA) Dividend History

Company News

• Hernia Repair Devices Market is Set to Attain Valuation of US$ 6.57 Billion by 2033 | Astute Analytica

  The global hernia repair devices market is projected to reach US$ 6.57 billion by 2033, driven by rising procedural volumes, technological advancements, and increasing adoption of minimally invasive techniques. Key trends include the shift towards mesh implants, competition between open and laparoscopic repair, and the growing use of robotic platforms and biologic/biosynthetic materials.

  GlobeNewswire Inc.

  Featured Companies: ISRG MDT
• TELA Bio Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

  TELA Bio, a medical technology company, announced the closing of its public offering of common stock and pre-funded warrants, raising $46 million. The company plans to use the proceeds for general corporate purposes.

  Benzinga
• Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Top Estimates

  Vertex (VRTX) delivered earnings and revenue surprises of 16.10% and 5.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: VRTX
• Rare Stock Picks In January 2024 - From 45 Discerning Analysts

  In our monthly Rare Stock Picks series, we're highlighting January 2024 investment picks. Click here for the list of January 2024 Buy recommendations.

  Seeking Alpha

  Featured Companies: AAL AGCO ALNY CERT CRNT CROX F FTNT GDL GTY HTGC HY IBM LCID MA MP MWA NBBK NFLX NXPI NXT OPI ORN PAYC PBDC PYPL RELY SHIP SSTK TG UPWK X
• TELA Bio, Inc. (TELA) Q2 2022 Earnings Call Transcript

  TELA earnings call for the period ending June 30, 2022.

  The Motley Fool